A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA® (sotagliflozin): •We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. •We are separately pursuing regulatory approval of ZYNQUISTA® (sotagliflozin) as a treatment for type 1 diabetes. The U.S. Food and Drug Administration, or FDA, issued complete response letters regarding our New Drug Application, or NDA, for ZYNQUISTA in type 1 diabetes in March 2019 and December 2024.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 50M | 50M | - | - | - | - |
| Net Income | -50M | -50M | -200M | -177M | -102M | -88M |
| EPS | $-0.14 | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| Free Cash Flow | -68M | -68M | -180M | -162M | -90M | -88M |
| ROIC | -29.3% | -32.1% | -81.4% | -92.0% | -61.5% | -77.3% |
| Gross Margin | 99.4% | 99.4% | - | - | - | - |
| Debt/Equity | 0.54 | 0.54 | 0.69 | 1.07 | 0.41 | 0.00 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -49M | -49M | -197M | -172M | -101M | -87M |
| Operating Margin | -98.2% | -98.2% | - | - | - | - |
| ROE | -46.8% | -39.7% | -137.3% | -190.2% | -87.0% | -65.0% |
| Shares Outstanding | 360M | 360M | 318M | 221M | 164M | 146M |
LEXICON PHARMACEUTICALS, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 99.4%. At current prices, the estimated annualized return to fair value is +3.3%.
LEXICON PHARMACEUTICALS, INC. (LXRX) has a 5-year average return on invested capital (ROIC) of -68.8%. This is below average and may indicate limited pricing power.
LEXICON PHARMACEUTICALS, INC. (LXRX) has a market capitalization of $615M. It is classified as a small-cap stock.
LEXICON PHARMACEUTICALS, INC. (LXRX) does not currently pay a regular dividend.
LEXICON PHARMACEUTICALS, INC. (LXRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
LEXICON PHARMACEUTICALS, INC. (LXRX) reported annual revenue of $50 million in its most recent fiscal year, based on SEC EDGAR filings.
LEXICON PHARMACEUTICALS, INC. (LXRX) has a net profit margin of -101.1%. The company is currently unprofitable.
LEXICON PHARMACEUTICALS, INC. (LXRX) generated $-68 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
LEXICON PHARMACEUTICALS, INC. (LXRX) has a debt-to-equity ratio of 0.54. This indicates moderate leverage.
LEXICON PHARMACEUTICALS, INC. (LXRX) reported earnings per share (EPS) of $-0.14 in its most recent fiscal year.
LEXICON PHARMACEUTICALS, INC. (LXRX) has a return on equity (ROE) of -39.7%. A negative ROE may indicate losses or negative equity.
LEXICON PHARMACEUTICALS, INC. (LXRX) has a 5-year average gross margin of 99.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for LEXICON PHARMACEUTICALS, INC. (LXRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LEXICON PHARMACEUTICALS, INC. (LXRX) has a book value per share of $0.30, based on its most recent annual SEC filing.